These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34753778)

  • 1. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
    Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
    Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
    Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
    BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
    BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
    Yang G; Xu H; Yang Y; Zhang S; Xu F; Hao X; Li J; Xing P; Hu X; Liu Y; Wang L; Lin L; Wang Z; Duan J; Wang J; Wang Y
    BMC Med; 2022 Aug; 20(1):277. PubMed ID: 36031613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.
    Wang L; Wu Y; Ren Z; Chu X; Chen J; Liu L; Zhao J; Yu X; Xie M; Su C
    Cancer Med; 2024 Jun; 13(12):e7335. PubMed ID: 38923311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.
    Huang Y; Zhao Y; Huang Y; Yang Y; Zhang Y; Hong S; Zhao H; Zhao S; Zhou T; Chen G; Zhou H; Ma Y; Zhou N; Zhang L; Fang W
    MedComm (2020); 2024 May; 5(5):e536. PubMed ID: 38685972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
    Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
    J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
    Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
    BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.
    Zhou H; Lv M; Li W; Wang Y; Wu J; Liu Q; Liu T; Cui Y; Li Q
    Clin Colorectal Cancer; 2024 Mar; 23(1):58-66. PubMed ID: 38177002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
    Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
    Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a pyrotinib-based regimen in non-small cell lung cancer patients harboring HER2 alterations: A real-world retrospective study.
    Wang X; Wang J; Chu Y; Hao J
    J Cancer Res Ther; 2023 Dec; 19(6):1663-1668. PubMed ID: 38156935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrotinib in
    Zhou C; Li X; Wang Q; Gao G; Zhang Y; Chen J; Shu Y; Hu Y; Fan Y; Fang J; Chen G; Zhao J; He J; Wu F; Zou J; Zhu X; Lin X
    J Clin Oncol; 2020 Aug; 38(24):2753-2761. PubMed ID: 32614698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study.
    Dai S; Zhang Y; Tan X; Luo F; Yan X
    Cancer Med; 2024 Jun; 13(11):e7256. PubMed ID: 38808952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
    Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
    J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
    Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
    Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.